Edoxaban safe treatment for kids at high risk for thromboembolism
Edoxaban safe treatment of kids at high risk for thromboembolism suggests a recent study published in the Journal of the American College of Cardiology
The ENNOBLE-ATE trial showed that edoxaban was safe for treatment of children at high risk for thromboembolism.
The goal of the trial was to evaluate edoxaban compared with standard of care anticoagulants among children at high risk for thromboembolism.
Study Design
• Randomized
• Parallel
• Open-label
• Stratified
Children with cardiac disease who were at high risk for thromboembolism were randomized to edoxaban (n = 109) vs. standard of care anticoagulants (n = 58). Standard of care anticoagulants included low molecular weight heparin and vitamin K antagonists.
• Total number of enrollees: 167
• Duration of follow-up: 12 months
• Mean patient age: 8 years
• Percentage female: 35%
Inclusion criteria:
• Children >38 weeks to <18 years of age
• Cardiac disease and at high risk for thromboembolism requiring ≥3 months of anticoagulant prophylaxis
Exclusion criteria:
• Symptomatic or asymptomatic arterial or venous thromboembolism
• Asymptomatic intracardiac thrombosis
• Mechanical heart valve
• Active bleeding or at high risk for bleeding
Other salient features/characteristics:
• Fontan surgery: 44%
• Kawasaki disease: 22%
• Heart failure: 4%
Principal Findings:
The primary outcome, major or clinically relevant nonmajor bleeding, occurred in 0.9% of the edoxaban group vs. 1.7% of the standard of care anticoagulant group.
Secondary outcomes:
• Thromboembolic events: 0% in the edoxaban group vs. 1.7% in the standard of care anticoagulant group
• Treatment emergent adverse events: 46.8% in the edoxaban group vs. 41.4% in the standard of care anticoagulant group
Among children at high risk for thromboembolism, edoxaban was safe. Edoxaban was associated with a low rate of clinically relevant major bleeding and thromboembolic events. Due to safety profile, once daily dosing, and no need for monitoring, edoxaban may be considered for treatment of children at high risk for thromboembolism.
References:
Portman MA, Jacobs JP, Newburger JW, et al., on behalf of the ENNOBLE-ATE Trial Investigators. Edoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease. J Am Coll Cardiol 2022;80:2301-10.
Keywords:Edoxaban,safe, treatment, kids, high, risk, thromboembolism, Journal of the American College of Cardiology, Portman MA, Jacobs JP, Newburger JW
